JBIO insider transactions
Jade Biosciences Inc. (JBIO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
JBIO insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Jade Biosciences Inc., latest first. Follow anyone to get their next filing.
- Mark EisnerDirector, since June 2026
- Christopher W. CainDirector, since April 2025
- Bradford D. DahmsChief Financial Officer, since July 2025
- Elizabeth BaltaOfficer, since April 2025
- Andrew James KingOfficer, since April 2025
- Tom FrohlichChief Executive Officer, Director, since April 2025+$44.4K
- Fairmount Funds Management LLCDirector, 10% owner, since April 2025
- Atlas Venture Fund XII, L.P.10% owner
- Erin LavelleDirector, since April 2025
- Lawrence Otto KleinDirector, since April 2025
- Eric DobmeierDirector, since April 2025
- Hetal KocinskyChief Medical Officer, since April 2025
- Jonathan QuickOfficer, since April 2025
- Ra Capital Management, L.P.10% owner+$1.55M
- Benjamin T DakeOfficer-$8.16M
- Marinus VerwijsChief Technical Officer, since March 2022-$647K
- George A EldridgeOfficer-$2.68M
- Hunter GilliesChief Medical Officer-$1.56M
- Donald J SantelDirector, since January 2023
- Joshua ResnickDirector
- Maha KatabiDirector, 10% owner
- Allison DorvalDirector, since July 2021
- David S. GrayzelDirector-$334K
- Mark T IwickiDirector
- Habib J DableDirector, since July 2023
- Timothy P NoyesChief Executive Officer, Director-$3.02M
- Ralph NivenChief Scientific Officer-$989K
- Timothy PigotChief Commercial Officer, since March 2023
Recent Form 3, 4, and 5 filings for JBIO
- SEC Form 4 filed by Director Eisner Mark4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SEC Form 3 filed by new insider Eisner Mark3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SEC Form 4 filed by Director Cain Christopher W.4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- Chief Financial Officer Dahms Bradford D. was granted 37,813 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- Officer Balta Elizabeth was granted 28,125 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- Chief Executive Officer Frohlich Tom was granted 78,750 shares, increasing direct ownership by 1,039% to 86,331 units (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- Officer King Andrew James was granted 41,250 shares, increasing direct ownership by 12% to 386,113 units (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- Director Fairmount Funds Management Llc was granted 1,333,126 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Dahms Bradford D.4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SEC Form 3 filed by new insider Dahms Bradford D.3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- Chief Executive Officer Frohlich Tom bought $44,400 worth of shares (6,000 units at $7.40) (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)